Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%
I Arany, SK Tyring, MA Stanley, MA Tomai, RL Miller… - Antiviral research, 1999 - Elsevier
The mechanism of action of imiquimod 5% cream applied topically to patients with genital
warts was evaluated in a double-blind, placebo-controlled study. Imiquimod (16 patients) or …
warts was evaluated in a double-blind, placebo-controlled study. Imiquimod (16 patients) or …
Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts
KR Beutner, SK Tyring, KF Trofatter Jr… - Antimicrobial agents …, 1998 - Am Soc Microbiol
Genital human papillomavirus infection is one of the most common sexually transmitted
diseases. Imiquimod is a new agent, an immune-response modifier, that has been …
diseases. Imiquimod is a new agent, an immune-response modifier, that has been …
Topical imiquimod: a review of its use in genital warts
CM Perry, HM Lamb - Drugs, 1999 - Springer
Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …
for application by the patient. It is the first agent of its class, the immune response modifiers …
Treatment of genital warts with an immune-response modifier (imiquimod)
KR Beutner, SL Spruance, AJ Hougham, TL Fox… - Journal of the American …, 1998 - Elsevier
Background: Genital warts are a common sexually transmitted disease caused by human
papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a …
papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a …
Imiquimod 5% cream (Aldara™)
S HB, O ML, T MA, M RL - Expert opinion on investigational drugs, 1998 - Taylor & Francis
Imiquimod is a novel synthetic molecule with potent immune-modifying activities. Formulated
in a 5% vanishing cream as Aldara™, this self-applied therapy has shown good efficacy and …
in a 5% vanishing cream as Aldara™, this self-applied therapy has shown good efficacy and …
Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study
TA Syed, SM Hadi, ZA Qureshi, SM Ali, MS Kwah - Journal of Infection, 2000 - Elsevier
Objective: The purpose of this double-blind, placebo-controlled study was to evaluate the
safety, clinical efficacy and tole-rability of imiquimod (2%) in cream to cure external genital …
safety, clinical efficacy and tole-rability of imiquimod (2%) in cream to cure external genital …
Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double‐blind, placebo‐controlled study
TA Syed, OA Ahmadpour, SA Ahmad… - The Journal of …, 1998 - Wiley Online Library
The purpose of this randomized, double‐blind, placebo‐controlled study was to determine
the clinical efficacy and tolerability of an analog of imiquimod (2%) in cream to cure genital …
the clinical efficacy and tolerability of an analog of imiquimod (2%) in cream to cure genital …
A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients
RJC Gilson, JL Shupack, AE Friedman-Kien… - Aids, 1999 - journals.lww.com
Objective: To assess the safety of imiquimod, an immune response modifier, in the topical
treatment of external anogenital warts in HIV-infected patients. Setting: Clinical sites in the …
treatment of external anogenital warts in HIV-infected patients. Setting: Clinical sites in the …
Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day
KH Fife, A Ferenczy, JM Douglas Jr… - Sexually transmitted …, 2001 - journals.lww.com
Background Medical therapy for genital warts remains suboptimal. The topical interferon and
cytokine inducer, imiquimod, has been proved effective for the treatment of external genital …
cytokine inducer, imiquimod, has been proved effective for the treatment of external genital …
An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women
SM Garland, R Waddell, A Mindel… - … journal of STD & …, 2006 - journals.sagepub.com
Our objective was to determine the optimal duration of treatment with imiquimod for external
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …